Your browser doesn't support javascript.
loading
Synergistic effect of simvastatin and romidepsin on gamma-globin gene induction
Cell Journal [Yakhteh]. 2019; 20 (4): 576-583
in English | IMEMR | ID: emr-199629
Responsible library: EMRO
ABSTRACT

Objective:

Hemoglobinopathies such as beta-thalassemia and sickle cell disease [SCD] are inherited disorders that are caused by mutations in beta-globin chain. Gamma-globin gene reactivation can ameliorate clinical manifestations of betathalassemia and SCD. Drugs that induce fetal hemoglobin [HbF] can be promising tools for treatment of beta-thalassemia and SCD patients. Recently, it has been shown that Simvastatin [SIM] and Romidepsin [ROM] induce HbF. SIM is a BCL11a inhibitor and ROM is a HDAC inhibitor and both of these drugs are Food and Drug Administration [FDA]-approved for hypercholesterolemia and cutaneous T-cell lymphoma respectively. Our aim was to evaluate the synergistic effects of these drugs in inducing HbF
Search on Google
Index: IMEMR (Eastern Mediterranean) Language: English Journal: Cell J. [Yakhteh] Year: 2019

Similar

MEDLINE

...
LILACS

LIS

Search on Google
Index: IMEMR (Eastern Mediterranean) Language: English Journal: Cell J. [Yakhteh] Year: 2019